Percheron Advances HMBD-002 Leukaemia Study as Capital Raising Drives Large Option Issue
Percheron’s HMBD-002 programme moved closer to clinical testing after the FDA cleared Vanderbilt Health’s investigator-sponsored study for up to 20 patients with relapsed or refractory acute myeloid leukaemia and related disease. Alongside that development, the company completed a $2.3 million capital raising and issued 575 million options tied to earlier rights issues and placements, applying for their ASX quotation; the issue includes 50 million options for joint lead managers as fees.

Comments